Let's Talk About a Personalized Approach to Antithrombotic Therapies
Back to course
Video Transcription
0:00
Hello, everyone, and it is my pleasure to have an esteemed group of experts as we are going to be talking about coronary artery disease and peripheral arterial disease as
0:16
the state-of-the-art antithrombotic therapies for both coronary and peripheral atherosclerosis.
0:22
I'm Professor Kelly Branch from the University of Washington, and it is my pleasure to have
0:26
wonderful colleagues that are really going to be talking about this field, which, of course,
0:32
we've known about for many years, but we have many new treatments, many exciting changes within this field, and we're going to be outlining those today. First, I have Professor Mark
0:43
Benaca, who's at the University of Colorado. I have Professor Jeff Barnes from the University
0:49
of Michigan, and Professor Roxanna Maran from Mount Sinai in New York, and it's a pleasure to
0:55
have all three of you here to talk about this very interesting topic today. So, let me go ahead
1:01
and start off, and we're going to be using first names because we're friends and colleagues here,
1:06
but I wanted to start off to get kind of an introduction to really bring us into the topic.
1:11
So, when we talk about coronary artery disease and peripheral arterial disease, we're talking
1:15
about atherosclerosis, but is this really the same disease, and how do these patients differ?
1:22
What is our current understanding? Jeff, I'm going to ask you first. Can you give us just a
1:26
little bit of an outline about kind of atherosclerosis within these different patient populations?
1:34
Well, you know, Kelly, I think it's a really good question, and at the core, yes, these diseases
1:40
stem from the same pathologic process, which is atherosclerotic buildup of plaque in an arterial
1:48
bed, but they also have really important differences that I think are essential for us to
1:53
understand. Now, both of them build up cholesterol, and at a certain point, there's a thrombotic
1:58
process that occurs, but in the coronary arteries, that tends to be a very sudden and severe event.
Video Summary
In this video discussion, experts discuss the use of antithrombotic therapies for coronary artery disease (CAD) and peripheral arterial disease (PAD). The experts explain that while CAD and PAD are both atherosclerotic diseases, they do have important differences. For CAD, the focus is on acute events, such as heart attacks, while PAD is a chronic condition with a higher risk of limb events. The discussion also explores the concept of risk stratification for patients with CAD and PAD. The experts emphasize the importance of considering both major adverse cardiovascular events (MACE) and major adverse limb events (MALE) as potential risks for these patients. The conversation then turns to the topic of antithrombotic therapies. It is noted that while there are established guidelines for CAD, there is still a need for more research and guidelines for PAD. The experts discuss the various treatment options, such as aspirin, statins, and dual antiplatelet therapy (DAPT), and highlight the importance of tailoring treatment to the individual patient. They also discuss the potential role of newer therapies, such as PCSK9 inhibitors and GLP-1 agonists, in reducing amputation and other major adverse limb events in patients with PAD. Overall, the experts emphasize the need for a personalized approach to antithrombotic therapy for CAD and PAD, considering both the cardiovascular and limb risks for each patient.
Keywords
antithrombotic therapies
coronary artery disease
peripheral arterial disease
atherosclerotic diseases
acute events
chronic condition
limb events
risk stratification
personalized approach
Android App Download IOS App Download Powered By